Department of Physiology, HeartOtago, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand.
University Heart and Vascular Centre, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
Am J Physiol Heart Circ Physiol. 2021 Jul 1;321(1):H162-H174. doi: 10.1152/ajpheart.00184.2021. Epub 2021 Jun 4.
Long-chain acylcarnitines (LCACs) are known to directly alter cardiac contractility and electrophysiology. However, the acute effect of LCACs on human cardiac function is unknown. We aimed to determine the effect of LCAC 18:1, which has been associated with cardiovascular disease, on the contractility and arrhythmia susceptibility of human atrial myocardium. Additionally, we aimed to assess how LCAC 18:1 alters Ca influx and spontaneous Ca release in vitro. Human right atrial trabeculae ( = 32) stimulated at 1 Hz were treated with LCAC 18:1 at a range of concentrations (1-25 µM) for a 45-min period. Exposure to the LCAC induced a dose-dependent positive inotropic effect on myocardial contractility (maximal 1.5-fold increase vs. control). At the 25 µM dose ( = 8), this was paralleled by an enhanced propensity for spontaneous contractions (50% increase). Furthermore, all LCAC 18:1 effects on myocardial function were reversed following LCAC 18:1 washout. In fluo-4-AM-loaded HEK293 cells, LCAC 18:1 dose dependently increased cytosolic Ca influx relative to vehicle controls and the short-chain acylcarnitine C3. In HEK293 cells expressing ryanodine receptor (RyR2), this increased Ca influx was linked to an increased propensity for RyR2-mediated spontaneous Ca release events. Our study is the first to show that LCAC 18:1 directly and acutely alters human myocardial function and in vitro Ca handling. The metabolite promotes proarrhythmic muscle contractions and increases contractility. The exploratory findings in vitro suggest that LCAC 18:1 increases proarrhythmic RyR2-mediated spontaneous Ca release propensity. The direct effects of metabolites on human myocardial function are essential to understand cardiometabolic dysfunction. For the first time, the fatty acid metabolite, long-chain acylcarnitine 18:1, is shown to acutely increase the arrhythmia susceptibility and contractility of human atrial myocardium. In vitro, this was linked to an influx of Ca and an enhanced propensity for spontaneous RyR2-mediated Ca release.
长链酰基辅酶 A(LCAC)已知可直接改变心肌的收缩性和电生理。然而,LCAC 对人体心脏功能的急性影响尚不清楚。我们旨在确定与心血管疾病相关的 LCAC18:1 对人心房心肌收缩性和心律失常易感性的影响。此外,我们旨在评估 LCAC18:1 如何改变体外 Ca 内流和自发性 Ca 释放。在 1 Hz 刺激下的 32 个人右心房小梁( = 32)用 LCAC18:1 处理,浓度范围为 1-25 µM,持续 45 分钟。LCAC 的暴露诱导心肌收缩力的剂量依赖性正变力作用(与对照相比最大增加 1.5 倍)。在 25 µM 剂量( = 8)时,这与自发性收缩的增强倾向(增加 50%)相平行。此外,LCAC18:1 对心肌功能的所有作用在用 LCAC18:1 冲洗后均逆转。在负载 fluo-4-AM 的 HEK293 细胞中,LCAC18:1 剂量依赖性地增加细胞溶质 Ca 内流相对于载体对照和短链酰基辅酶 A C3。在表达肌浆网 Ca 释放通道(RyR2)的 HEK293 细胞中,这种增加的 Ca 内流与 RyR2 介导的自发性 Ca 释放事件的增加倾向相关。我们的研究首次表明,LCAC18:1 直接和急性改变人心肌功能和体外 Ca 处理。该代谢物促进致心律失常的肌肉收缩并增加收缩性。体外的探索性发现表明,LCAC18:1 增加了致心律失常 RyR2 介导的自发性 Ca 释放倾向。代谢物对人心肌功能的直接影响对于理解心脏代谢功能障碍至关重要。长链酰基辅酶 A18:1 是脂肪酸代谢物,首次显示其可急性增加人心房心肌的心律失常易感性和收缩性。在体外,这与 Ca 内流的增加和自发性 RyR2 介导的 Ca 释放倾向增强有关。